From Financial News Media (FNM) this morning:

From Financial News Media (FNM) this morning:

https://www.financialnewsmedia.com/

Check out their "Breaking News" on MBRX ... I expect CYDY to get lots of "Breaking News" and similar write ups... while they're saying it's 100% effective am not a scientist or medical person so I don't know how their drug stacks up with Leronlimab in terms of side effects:

https://www.financialnewsmedia.com/news-mbrx/

Meanwhile that biotech has seen a nearly 200% increase in pps this morning on that news with heavy volume.

According to TD Ameritrade:
Moleculin Biotech shares are trading higher after it says that independent research found 2-deoxy-D-glucose (2-DG)to reduce replication of coronavirus by 100% in the Vitro Testing. The company also noted the 2-DG is an active compound in its WP1122 Drug.


In one of the write ups on FNM is the following about CytoDyn as it's listed with the likes of Amazon and Clorox :

Quote:

---

In other healthcare news of note:

CytoDyn Inc. (OTCQB: CYDY) recently announced that the first two COVID-19 patients have been treated with leronlimab under the Company's Phase 2 randomized clinical trial, which is for patients with mild-to-moderate indications. The Company anticipates that enrollment of more patients will accelerate this week at multiple clinical sites.

In addition, the Company's investigational new drug, leronlimab, has now been administered to 15 severely ill COVID-19 patients at four hospitals, 10 patients treated at a leading medical center in the New York City area and five patients at three other hospitals, all under an emergency investigational new drug (EIND), which were granted by the U.S. Food and Drug Administration (FDA) for each individual patient.

---